18605-43-1 Usage
Description
0,11-DIMETHOXY-6-METHYL-5,6-DIHYDRO-4H-DIBENZO[DE,G]QUINOLINE is a complex chemical compound belonging to the dibenzo[de,g]quinoline family. It features two methoxy groups and a methyl group within its molecular structure, which may contribute to its potential pharmacological properties. 0,11-DIMETHOXY-6-METHYL-5,6-DIHYDRO-4H-DIBENZO[DE,G]QUINOLINE has been of interest for its possible applications in the development of new drugs, as well as in the fields of organic synthesis and medicinal chemistry. Further research is necessary to fully comprehend its properties and potential uses.
Uses
Used in Pharmaceutical Development:
0,11-DIMETHOXY-6-METHYL-5,6-DIHYDRO-4H-DIBENZO[DE,G]QUINOLINE is used as a compound in pharmaceutical development for its potential pharmacological properties. Its unique structure and possible biological activities make it a candidate for the creation of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, 0,11-DIMETHOXY-6-METHYL-5,6-DIHYDRO-4H-DIBENZO[DE,G]QUINOLINE is used as a key intermediate or building block for the synthesis of more complex molecules, taking advantage of its unique structural features.
Used in Medicinal Chemistry:
0,11-DIMETHOXY-6-METHYL-5,6-DIHYDRO-4H-DIBENZO[DE,G]QUINOLINE is utilized in medicinal chemistry as a compound with potential biological activities. Its structure may be optimized to develop new therapeutic agents targeting various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 18605-43-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,6,0 and 5 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 18605-43:
(7*1)+(6*8)+(5*6)+(4*0)+(3*5)+(2*4)+(1*3)=111
111 % 10 = 1
So 18605-43-1 is a valid CAS Registry Number.
18605-43-1Relevant articles and documents
Convenient synthesis of (S)-(+)-apomorphine from (R)-(-)-apomorphine
Davis,Seyhan,Soine,Smith
, p. 1056 - 1058 (1980)
A method was devised for preparing (S)-(+)-apomorphine from (R)-(-)-apomorphine. Dehydrogenation of the dimethyl ether of (R)-(-)-apomorphine with 10% palladium-on-carbon carbon followed by reduction with sodium cyanoborohydride under acidic conditions resulted in quantitative racemization to given (R,S)-apomorphine dimethyl ether, which then was resolved with (-)-tartaric acid. Ether cleavage of (S)-(+)-apomorphine dimethyl ether (-)-tartrate with hydriodic acid in acetic anhydride yielded (S)-(+)-apomorphine, which was isolated as the hydrochloride salt in 99% enantiomeric excess.
PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
-
, (2021/02/12)
The present invention relates to pharmaceutical compositions for administration to mammals that include (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient that provides pharmacokinetic profiles useful for the treatment of neurodegenerative diseases.
The autoxydation of apomorphin
Linde,Ragab
, p. 683 - 687 (2007/10/07)
-
